Related Experiment Video
Updated: Jun 21, 2025

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram
Ayse Irem Yasin1, Mahmut Uluganyan2, Zehra Sucuoglu Isleyen3
1Department of Medical Oncology, Bezmialem Vakıf University, Huzur Mah. Cumhuriyet Cad., 34396, Istanbul, Turkey. ayseiremyasin@gmail.com.
Insights
Ribociclib, a breast cancer treatment, shows a low risk of early heart problems. A study using Holter ECG monitoring found no significant cardiac rhythm changes in patients after three months of treatment.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Ribociclib is a targeted therapy used for metastatic breast cancer.
- Assessing the cardiac safety of oncology drugs is crucial for patient management.
Purpose of the Study:
- To evaluate the cardiac safety profile of ribociclib using 24-hour Holter electrocardiogram (ECG).
- To determine if ribociclib treatment affects cardiac rhythm in breast cancer patients.
Main Methods:
- The study included 42 female metastatic breast cancer patients.
- Rhythm Holter ECGs were performed before treatment and after three months of ribociclib initiation.
- Patients received ribociclib in combination with fulvestrant or aromatase inhibitors.
Main Results:
- No instances of cardiotoxicity were observed in any patients.
- Comparison of Holter ECG results before and after three months showed no statistically significant differences in cardiac rhythm.
- The mean age of the patient cohort was 56.36 ± 12.73 years.
Conclusions:
- This study provides the first evaluation of ribociclib's cardiac rhythm effects using Holter ECG.
- Findings suggest that ribociclib has a low risk of causing early cardiotoxicity.
- Ribociclib can be considered safe regarding cardiac rhythm in the early stages of treatment.
Objective:
We aimed to evaluate cardiac safety profile of ribociclib with 24-h rhythm Holter ECG.
Material And Method:
Forty-two female metastatic breast cancer patients were included in the study. Rhythm Holter ECG was performed before starting treatment with ribociclib and after 3 months of the treatment initiation.
Results:
The mean age of the patients was 56.36 ± 12.73. 52.4% (n = 22) of the patients were using ribociclib in combination with fulvestrant and 47.6% (n = 20) with aromatase inhibitors. None of the patients developed cardiotoxicity. When the rhythm Holter results before and in third month of the treatment were compared, there was no statistically significant difference.
Conclusion:
This is the first study evaluating effects of ribociclib treatment on cardiac rhythm with Holter ECG. The findings suggested ribociclib has a low risk of causing early cardiotoxicity.
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Correlation between ECG and Cardiac Cycle
A cardiac action potential originates in the SA node and spreads throughout the atria and the AV node in approximately 0.03 seconds. This results in the P wave in an ECG and triggers atrial contraction. The action potential is then briefly slowed at the AV node, allowing the atria to contract and fill the ventricles with blood before...
Electrocardiogram
Three major waveforms are present in a typical ECG recording: the P wave, the QRS complex, and...
Electrophysiology of Normal Cardiac Rhythm
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...